HeartBeam (NASDAQ: BEAT) announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating the credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain. The proof-of-concept study evaluated 184 patients and found that the algorithm achieved an "area under the curve" (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms. The AUC rose to 92.9% when a personal, symptom-free baseline ECG was available for comparison, according to the company.
The study results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program. HeartBeam is a medical technology company focused on transforming cardiac care by providing powerful cardiac insights. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence.
Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement.
The full press release is available at https://ibn.fm/ainxV. For more information about HeartBeam and its cleared indications, visit https://www.heartbeam.com/indications. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
This study underscores the potential of portable ECG technology to improve early detection of heart attacks, which could reduce time to treatment and improve patient outcomes. By enabling risk assessment outside of traditional clinical settings, the HeartBeam device may help address the challenge of timely diagnosis in patients with chest pain, a common symptom of acute coronary syndrome.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's filings with the SEC. The company undertakes no duty to update this information unless required by law.